Cargando…

Updates in pharmacotherapy of heart failure with reduced ejection fraction

Heart failure is a common entity encountered in healthcare with a vast socioeconomic impact. Recent advances in pharmacotherapy have led to the development of novel therapies with mortality benefits, improvement in heart failure symptoms and hospitalizations. This article is intended to explore thos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Espinoza, Clifton, Alkhateeb, Haider, Siddiqui, Tariq
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review article on Heart Failure Update and Advances in 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039644/ https://www.ncbi.nlm.nih.gov/pubmed/33850913 http://dx.doi.org/10.21037/atm-20-4640

Ejemplares similares

Narrative review: the holy grail: update on pharmacotherapy for heart failure with preserved ejection fraction
por: Paz, Pablo Alejandro, et al.
Publicado: (2021)

Right Heart Phenotype in Heart Failure With Preserved Ejection Fraction
por: Guazzi, Marco, et al.
Publicado: (2021)

Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition
por: Margonato, Davide, et al.
Publicado: (2020)

Editorial for “Heart Failure Update and Advances in 2021”
por: Mukherjee, Debabrata, et al.
Publicado: (2021)

Non-invasive intraventricular pressure differences estimated with cardiac MRI in subjects without heart failure and with heart failure with reduced and preserved ejection fraction
por: Londono-Hoyos, Francisco, et al.
Publicado: (2019)

Efficacy of Ranolazine to Improve Diastolic Performance in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis
por: Putri, Desak Ketut Sekar Cempaka, et al.
Publicado: (2023)

Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction
por: Salah, Khibar, et al.
Publicado: (2019)

Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction
por: Son, Mi Kyoung, et al.
Publicado: (2020)

Narrative review of pharmacotherapy for transthyretin cardiac amyloid
por: Cruz Rodriguez, Jose B., et al.
Publicado: (2021)

Prognostic impacts of changes in left ventricular ejection fraction in heart failure patients with preserved left ventricular ejection fraction
por: Yoshihisa, Akiomi, et al.
Publicado: (2020)

Implantation of a vagus nerve stimulator for patients with heart failure with reduced ejection fraction: An educational video
por: Al Rameni, Dina, et al.
Publicado: (2022)

Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
por: Benini, Annachiara, et al.
Publicado: (2022)

Baseline characteristics of patients with heart failure and preserved ejection fraction at admission with acute heart failure in Saudi Arabia
por: Abohammar, Samah, et al.
Publicado: (2017)

Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure
por: Gijsberts, Crystel M, et al.
Publicado: (2016)

The New Heart Failure Association Definition of Advanced Heart Failure
por: Metra, Marco, et al.
Publicado: (2019)

Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study
por: Ganesananthan, Sashiananthan, et al.
Publicado: (2020)

Development of algorithms for determining heart failure with reduced and preserved ejection fraction using nationwide electronic healthcare records in the UK
por: Sundaram, Varun, et al.
Publicado: (2022)

Antithrombotics in heart failure
por: Miličić, Davor, et al.
Publicado: (2014)

Optimal diuretic strategies in heart failure
por: Suri, Sarabjeet S., et al.
Publicado: (2021)

Ultrafiltration in Acute Heart Failure
por: Costanzo, Maria Rosa
Publicado: (2019)

Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis
por: Beale, Anna L, et al.
Publicado: (2019)

Diastolic index as a short-term prognostic factor in heart failure with preserved ejection fraction
por: Hoshida, Shiro, et al.
Publicado: (2020)

Reporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic review
por: Zheng, Sean L, et al.
Publicado: (2016)

Mild aortic valve disease and the diastolic pressure–volume relationship in heart failure with preserved ejection fraction
por: Verbrugge, Frederik H, et al.
Publicado: (2021)

Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction
por: van Essen, Bart J., et al.
Publicado: (2022)

State-of-the-art Structural Interventions in Heart Failure
por: Park, Jeffrey, et al.
Publicado: (2019)

Extracellular cardiac matrix biomarkers in patients with reduced ejection fraction heart failure as predictors of response to cardiac resynchronisation therapy: a systematic review
por: McAloon, Christopher J, et al.
Publicado: (2017)

Prognostic value of left ventricular mitral annular longitudinal displacement obtained by tissue Doppler imaging in patients with heart failure with reduced ejection fraction
por: Sengeløv, Morten, et al.
Publicado: (2021)

Revascularization in ischemic heart failure with reduced left ventricular ejection fraction. The impact of complete revascularization
por: Pyka, Łukasz, et al.
Publicado: (2017)

Rationale and design of the preserved versus reduced ejection fraction biomarker registry and precision medicine database for ambulatory patients with heart failure (PREFER-HF) study
por: Abboud, Andrew, et al.
Publicado: (2021)

Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study
por: Hage, Camilla, et al.
Publicado: (2015)

Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis
por: Zheng, Sean Lee, et al.
Publicado: (2018)

Current state-of-the-art of device therapy for advanced heart failure
por: Lee, Lawrence S., et al.
Publicado: (2014)

Narrative review in the current role of angiotensin receptor-neprilysin inhibitors
por: Cruz Rodriguez, Jose B., et al.
Publicado: (2021)

Sacubitril/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: a meta-analysis
por: Basile, Christian, et al.
Publicado: (2023)

Focusing on Referral Rather than Selection for Advanced Heart Failure Therapies
por: Thorvaldsen, Tonje, et al.
Publicado: (2019)

Medications for specific phenotypes of heart failure with preserved ejection fraction classified by a machine learning-based clustering model
por: Sotomi, Yohei, et al.
Publicado: (2023)

Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan
por: Agostoni, Piergiuseppe, et al.
Publicado: (2019)

Ischaemia change with revascularisation versus medical therapy in reduced ejection fraction
por: Mentz, Robert J, et al.
Publicado: (2015)

Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England
por: Kolovos, Spyros, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6i2ve5n2o2dspq509pbl36g44q